Previous 10 | Next 10 |
BIGZ was launched earlier this year and has since done a lot of nothing in terms of movement. The fund launched at a $20 NAV and last closed at $19.96, a large move with the prior close helped add $0.55 (August 27th). I view BIGZ as a long-term type holding that can provide income...
On Aug. 16, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q2 2021. I curated a list of some of the best-performing hedge funds and looked into their holdings at the end of June 2021. Several common themes appear whe...
PLEASANTON, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit. 10x Genomics’ management is scheduled to present on Tuesday, August 10 th...
10x Genomics, Inc. (TXG) Q2 2021 Earnings Conference Call August 04, 2021, 04:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug...
10x Genomics (NASDAQ:TXG): Q2 GAAP EPS of -$0.10 beats by $0.16. Revenue of $115.8M (+169.9% Y/Y) beats by $2.95M. 10x Genomics is maintaining its previously announced full year 2021 revenue guidance of $480 million to $500 million vs. consensus of $496.62M, representing 61% to 67% growth ove...
PLEASANTON, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Revenue was $115.8 million for the second quarter, representing a 170% increase over the...
10x Genomics (TXG) has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories (BIO).The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringement clai...
Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratori...
Artystarty/iStock via Getty Images Thanks to the prospects of earning a spot in the S&P 500 Index, Moderna (MRNA) jumped ~23.0% this week to breeze past $100B market capitalization. The frontrunner in COVID-19 vaccine development has taken less than three yea...
Sundry Photography/iStock Editorial via Getty Images 10x Genomics ([[TXG]] -2.3%) says that its Chromium X series, a next-generation system for single cell analysis, is now commercially available. Chromium X provides routine million cell experiments down to two cents per cell. The system also...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...